Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Depreciation & Amortization (CF) (2020 - 2025)

Neuroone Medical Technologies' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $65523.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 0.61% year-over-year to $65523.0; the TTM value through Dec 2025 reached $262075.0, up 3.48%, while the annual FY2025 figure was $261679.0, 6.03% up from the prior year.
  • Depreciation & Amortization (CF) reached $65523.0 in Q4 2025 per NMTC's latest filing, up from $64324.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $66594.0 in Q2 2025 to a low of $19294.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $47694.6, with a median of $57807.5 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 87.03% in 2023, then grew 0.31% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $25161.0 in 2021, then skyrocketed by 42.64% to $35889.0 in 2022, then soared by 63.44% to $58657.0 in 2023, then grew by 11.03% to $65127.0 in 2024, then grew by 0.61% to $65523.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Depreciation & Amortization (CF) are $65523.0 (Q4 2025), $64324.0 (Q3 2025), and $66594.0 (Q2 2025).